InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

Separately, Piper Sandler restated an “overweight” rating and set a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th.

InspireMD Stock Down 0.4 %

NSPR stock opened at $2.75 on Monday. The firm has a market capitalization of $68.56 million, a PE ratio of -3.62 and a beta of 0.90. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.85. The stock’s 50 day moving average is $2.79 and its 200-day moving average is $2.51.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same quarter last year, the business posted ($0.24) earnings per share. On average, equities research analysts anticipate that InspireMD will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of InspireMD

A hedge fund recently raised its stake in InspireMD stock. Rosalind Advisors Inc. boosted its holdings in InspireMD, Inc. (NYSE:NSPR) by 266.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,513,641 shares of the company’s stock after buying an additional 1,827,579 shares during the period. InspireMD makes up 4.6% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 8th biggest holding. Rosalind Advisors Inc. owned approximately 10.08% of InspireMD worth $6,272,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.